Global Pulmonary Hypertension Summit 2026, Barcelona, 4–8 November 2026: Working Together Towards the Future of Pulmonary Hypertension, Louise Bouman reporting

From 4 to 8 November 2026, the first Global Pulmonary Hypertension Summit (GPHS), organised by PHA Europe & Global, took place in Barcelona. Around 40 patient organisations from 35 countries came together with physicians, researchers and representatives from the pharmaceutical industry. Louise Bouman attended on behalf of Stichting Pulmonale Hypertensie (the Dutch Pulmonary Hypertension Association). The summit focused on international collaboration, scientific developments and the important role of patients in improving research, care and quality of life.

International collaboration and the patient voice

  • Representatives from several international organisations shared their experiences and initiatives. Victor Gascón Moreno from the Global Allergy & Airways Patient Platform (GAAPP) highlighted the importance of collaboration between patient organisations worldwide.
  • Steve Van Wormer, known for I’m Aware That I’m Rare: The phaware Podcast, emphasised the need for accessible and reliable patient information and introduced the Heart Works platform.
  • Personal stories also played an important role. Eric Borstein shared his experiences of living with pulmonary hypertension and his involvement in the PHenomenal Hope Team.
  • Professor Georg Hansmann discussed developments in paediatric pulmonary hypertension care, including clinical guidelines, risk assessment and research into potential new treatment approaches.
  • Anton Morkin shared his family’s experience with a TBX4 genetic condition affecting his son and explained how this led to the establishment of TBX4Life, an initiative raising awareness and supporting research and families affected by TBX4-related conditions.

These contributions highlighted the importance of combining scientific knowledge with lived experience.

New treatment approaches: moving beyond symptom control towards remission

Professor Hossein-Ardeschir Ghofrani provided an overview of developments in pulmonary hypertension treatment. One of his key messages was that the ultimate treatment goal in pulmonary arterial hypertension should go beyond symptom improvement. He highlighted remission as an important future treatment goal. Treatment decisions should not be based on symptoms alone. Objective measurements, including pulmonary vascular resistance (PVR) and right ventricular function, are essential in assessing disease status and treatment response.

Sotatercept was also discussed in detail. This treatment targets biological signalling pathways involved in pulmonary vascular remodelling. Potential effects on the right ventricle were highlighted, as well as the importance of assessing the individual benefit-risk balance for each patient.

Another promising development is mosliciguat, an inhaled treatment being investigated for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The phase 2 PHocus study showed promising results, including improvements in pulmonary vascular resistance and six-minute walk distance compared with placebo.

These findings have supported the progression to the international phase 3 PHRONTIER study, which aims to confirm the potential benefits in a larger patient population.

New treatment strategies and ongoing research

Several pharmaceutical and biotechnology companies presented their ongoing research into new treatments and alternative drug delivery approaches.

  • AOP Health discussed the TripleTRE study, which investigates the earlier use of prostacyclin therapy in patients with PAH.
  • The TRUST survey was also presented, highlighting the experiences of patients using subcutaneous treprostinil. Pain at the infusion site remains an important treatment burden. From a patient perspective, it is essential that the duration and impact of this pain are fully recognised when evaluating treatment options.
  • Liquidia presented L606, an investigational sustained-release formulation of treprostinil administered through inhalation. Inhibikase discussed IKT-001, a new formulation of imatinib being investigated to improve tolerability while retaining its potential therapeutic effects in PAH.
  • Cereno Scientific presented CS1, an investigational oral treatment that aims to influence several disease-related processes through epigenetic modulation, including vascular remodelling, inflammation, thrombosis and fibrosis.Following encouraging findings from a phase 2a study, the international phase 2b EPIMODE study is investigating CS1 in approximately 126 patients with pulmonary arterial hypertension . Pulmonary vascular resistance is the primary endpoint, while right ventricular function, quality of life and clinical worsening are also being assessed.

Together, these developments illustrate how research is expanding beyond traditional treatment approaches, exploring new biological targets and potentially less burdensome ways of delivering treatment.

PHEPA: empowering patients through education

During the summit, Louise Bouman and Hall Skaara presented the Pulmonary Hypertension Expert Patient Academy (PHEPA), an educational initiative developed through collaboration between the Alliance for Pulmonary Hypertension and PHA Europe, with the involvement of ERN-LUNG. PHEPA aims to strengthen the knowledge and skills of people living with pulmonary hypertension who want to become active and informed patient representatives.

The programme covers topics including pulmonary hypertension, treatments, clinical research and patient involvement. It helps participants develop the knowledge and confidence needed to contribute meaningfully to research, healthcare and policy discussions. The underlying principle is that patient participation should go beyond sharing personal experiences. Patients should have the knowledge, skills and opportunities to contribute as informed partners and help shape decisions that affect their lives.

Stronger together for the future

The first Global Pulmonary Hypertension Summit demonstrated the importance of bringing together the global PH community. Scientific research, new treatment approaches and patient involvement are all advancing, but progress is not only about developing new medicines.

Access to specialised care, reliable information, quality of life and recognition of the daily burden of treatment are equally important.

Patient organisations have a vital role to play in this process: connecting people, sharing knowledge, strengthening international collaboration and ensuring that the patient perspective is included from the earliest stages of research and decision-making.

The key message from Barcelona: by bringing together our knowledge, experiences and strengths across borders, we can work towards a better future for everyone living with pulmonary hypertension.

Photos: from left: Louise Bouman with Steve von Wormer, the lecture room, and Louise and Hall Skaara presenting the PH Expert Patient Academy (PHEPA)

TRANSLATE »
Scroll to Top